Table 1. Characteristics of cohorts.
| Cohort | Healthy Control | T1D | MSb | SLEc |
| n | 181 | 48 | 55 | 20 |
| agea | 36±16 | 33±12 | 37±14 | 48±14 |
| (18–68) | (18–74) | (22–63) | (25–79) | |
| % Female | 57 | 42.4 | 83.9 | 70.0 |
| % Caucasian | 86.6 | 94.7 | 98.4 | 95.0 |
| % non-Hispanic | 97.8 | 96.4 | 100 | 80 |
| Disease status | NAd | 200 – 22,488 days | 94% RRMS | 93% arthritis |
| since diagnosis | 3% PPMS | 87% skin | ||
| (ave: 6537, SD 5264) | 3% SPMS | 31% renal | ||
| 25% pleurisy | ||||
| Current Immuno- | None | None | 55% untreatede | 63% HCQ |
| modulatory | 40% Tysabri | 37% Prednisone | ||
| medications at | 3% Copaxone | 16% MMF | ||
| time of draw | 2% Interferons | 5% methotrexate | ||
| 5% azathioprine | ||||
| 5% belimumab | ||||
| IL2RArs2104286f | ||||
| A/A | 106 (0.586) | 24 (0.500) | 35 (0.636) | NDg |
| A/G | 68 (0.376) | 16 (0.333) | 13 (0.236) | ND |
| G/G | 6 (0.033) | 8 (0.167) | 7 (0.127) | ND |
| Freq A | 0.778 | 0.667 | 0.755 | ND |
| Freq G | 0.222 | 0.333 | 0.245 | ND |
a average ± SD years (range).
a ave ± SD (range).
b Relapsing Remitting, Primary Progressive and Secondary Progressive Multiple Sclerosis.
c SLE disease characteristics were determined by organ involvement at any point in the subjects disease course; HCQ- hydroxychloroquine; MMF- mycophenylate mofetil.
d Not Applicable.
e untreated includes subjects not on immune modulatory drugs >3 months prior to blood draw
f n (frequency).
g Not Determined.